{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:35:21Z","timestamp":1772753721418,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T00:00:00Z","timestamp":1205107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> To describe our 3\u2010year experience in the long\u2010term efficacy and safety of percutaneous ethanol injection therapy (PEIT), as an alternative to surgery for the management of patients with primary hyperparathyroidism (p\u2010HPT).<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Prospective study with a mean follow\u2010up of 19\u00b76\u00a0\u00b1 10\u00b76\u00a0months.<\/jats:p><jats:p><jats:bold>Patients\u2002<\/jats:bold> Our study population included 19 consecutive high risk patients with p\u2010HPT, who met the criteria for surgery.<\/jats:p><jats:p><jats:bold>Measurements\u2002<\/jats:bold> Under ultrasonic guidance, ethanol (95%) was injected into parathyroid glands with a volume of \u2265\u00a00\u00b715\u00a0cm<jats:sup>3<\/jats:sup>. With the aim of normalizing intact parathormone (iPTH) values, repeated ethanol injections were carried out, in an interval of 2\u00a0weeks, until normalization of iPTH was reached or until no residual blood supply was detected by ultrasound in the gland. Biochemical parameters were monitored throughout the study.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> At 6\u2010month follow\u2010up, normalization of iPTH levels (10\u201365\u00a0ng\/l) was achieved in 11 (58%) patients (responders). Of the eight remaining patients (nonresponders), six patients had reduced (but not normalized) iPTH levels and two patients required parathyroid surgery. Seventeen (11 responders and 6 nonresponders) of the 19 patients (89\u00b75%) became normocalcaemic (serum Ca\u00a0\u2264\u00a02\u00b757\u00a0mmol\/l) and remained so for a mean follow\u2010up of 21\u00a0months (8\u201339\u00a0months). The odds ratio (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b705) of response <jats:italic>vs.<\/jats:italic> no response to PEIT was 16\u00b77\u2010fold for pretreatment iPTH\u00a0&lt;\u00a0200 <jats:italic>vs<\/jats:italic>.\u00a0&gt;\u00a0200\u00a0ng\/l. The only complication was a transient dysphonia noticed in three patients.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> PEIT is a safe and effective nonsurgical treatment for patients with p\u2010HPT, who are unsuitable for surgical intervention.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2008.03238.x","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T01:49:18Z","timestamp":1205200158000},"page":"542-548","source":"Crossref","is-referenced-by-count":28,"title":["Percutaneous ethanol injection therapy: a surgery\u2010sparing treatment for primary hyperparathyroidism"],"prefix":"10.1111","volume":"69","author":[{"given":"Spyros","family":"Stratigis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Stylianou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Mamalaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Perakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftheria","family":"Vardaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Tzenakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Katsipi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stathis","family":"Papavasiliou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros","family":"Yarmenitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kyriazis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Daphnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,9,10]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021370"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp032200"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/msy.1998.91826"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.155.3.3889999"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.d01-1752.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00910-7"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2005.00214.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl620"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.373"},{"key":"e_1_2_5_11_2","first-page":"412","article-title":"Ultrasound\u2010guided percutaneous fine\u2010needle ethanol injection into parathyroid glands in secondary hyperparathyroidism","volume":"7","author":"Giangrande A.","year":"1992","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"e_1_2_5_12_2","first-page":"iii31","article-title":"Guidelines for PEIT of the parathyroid glands in chronic dialysis patients","volume":"18","author":"Fukagawa M.","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.74.886.740905"},{"key":"e_1_2_5_14_2","first-page":"561","article-title":"Non\u2010surgical therapy of primary hyperparathyroidism","volume":"94","author":"Howell P.","year":"2001","journal-title":"Journal of Oklahoma State Medical Association"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93115-P"},{"key":"e_1_2_5_16_2","first-page":"375","article-title":"Results of ultrasonically guided percutaneous ethanol injection into parathyroid adenomas in primary hyperparathyroidism","volume":"129","author":"Verg\u00e8s B.L.","year":"1993","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003300050587"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb00349.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-62-744-1037"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-7-593"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1210\/jcem.83.8.5006","article-title":"Profile of a clinical practice: Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons","volume":"83","author":"Sosa J.A.","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.140.5.472"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200205000-00008"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.13.2.105"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-005-0239-y"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2005.08.026"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1772"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-5-199609010-00002"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020890"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2001-010385"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020667"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711203372104"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0842"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2008.03238.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2008.03238.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:58:13Z","timestamp":1697230693000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2008.03238.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1111\/j.1365-2265.2008.03238.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03238.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,10]]}}}